Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Lowered by StockNews.com

StockNews.com downgraded shares of Aclaris Therapeutics (NASDAQ:ACRS) from a hold rating to a sell rating in a research note released on Thursday morning.

Separately, HC Wainwright reissued a “neutral” rating on shares of Aclaris Therapeutics in a report on Tuesday, September 17th. One investment analyst has rated the stock with a sell rating and six have assigned a hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $9.00.

Aclaris Therapeutics Price Performance

NASDAQ:ACRS traded up $0.16 during trading hours on Thursday, reaching $2.61. 557,666 shares of the stock were exchanged, compared to its average volume of 995,991. Aclaris Therapeutics has a twelve month low of $0.59 and a twelve month high of $5.61. The firm has a 50 day moving average of $1.32 and a 200 day moving average of $1.24. The stock has a market cap of $186.22 million, a PE ratio of -3.20 and a beta of 0.10.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). The firm had revenue of $4.35 million for the quarter, compared to analyst estimates of $8.31 million. Aclaris Therapeutics had a negative return on equity of 53.18% and a negative net margin of 183.28%. Equities research analysts anticipate that Aclaris Therapeutics will post -0.65 earnings per share for the current year.

Institutional Investors Weigh In On Aclaris Therapeutics

Large investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. bought a new stake in Aclaris Therapeutics in the 1st quarter valued at $39,000. SG Americas Securities LLC raised its stake in Aclaris Therapeutics by 69.5% in the 1st quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 13,461 shares during the period. Russell Investments Group Ltd. raised its stake in Aclaris Therapeutics by 5,265.1% in the 1st quarter. Russell Investments Group Ltd. now owns 62,772 shares of the biotechnology company’s stock valued at $78,000 after acquiring an additional 61,602 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in Aclaris Therapeutics in the 2nd quarter valued at $119,000. Finally, Assenagon Asset Management S.A. bought a new stake in Aclaris Therapeutics in the 3rd quarter valued at $214,000. Institutional investors own 98.34% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.